TSX Venture: QPT
EDMONTON, Nov. 1, 2011 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT)
("Quest" or the "Company"), a pharmaceutical company developing and
commercializing products for the treatment of cancer, today announced
that it will be making a presentation at the 2nd Biennial Meeting of the Asian Society of Gynecologic Oncology, in
Seoul, South Korea, November 3-5. The presentation, entitled "Targeting
Dendritic Cells to Create a More Powerful Immune Response: A New
Approach for the Immunotherapy of Ovarian Cancer using anti-CA125 MAb,
Oregovomab", will be presented by Dr. Chris Nicodemus, Chief Scientific
Officer of Advanced Immune Therapeutics and Chairman of Quest's
Clinical Advisory Board. Dr. Jonathan S. Berek, Professor and Director,
Stanford Women's Cancer Center, Stanford Cancer Institute, Stanford
University School of Medicine, and Chair, Cooperative Ovarian Cancer
Group, Stanford, California , is one of the co-authors of this
presentation, along with Dr. Madi R. Madiyalakan, CEO of Quest. Dr.
Berek has also been invited to make a presentation on 'Genetics of
Ovarian Cancer' during the conference.
The Company's presentation will highlight its clinical experience with
the immunotherapy of ovarian cancer using oregovomab, its unique
mechanism in targeting dendritic cells to activate cytotoxic T cell
responses, and the Company's strategy of using combinatorial therapies
(chemotherapy and/or immuno-adjuvants) to better mobilize anti-tumor
immunity. Dendritic cell based immunotherapeutic strategies are gaining
momentum in recent days, especially after the award of this year's
Noble Prize in Medicine for the discovery of the central role of
dendritic cells in mobilizing the adaptive immune system.
"With a large shareholder base in South Korea, this is an excellent
opportunity for Quest to present to the Asian gynecologic oncology
community our unique approach for immunotherapy of ovarian cancer",
said Dr. Madiyalakan, who will also be attending the ASGO conference.
The Company is in the process of translating its valuable intellectual
property into commercial success by conducting three carefully planned
proof-of-concept clinical trials to establish the superiority of
combinatorial immunotherapy either with front-line chemotherapy
consisting of carboplatin/paclitaxel in ovarian cancer, gemcitabine in
pancreatic cancer, or with the addition of an immunoadjuvant. The
Company hopes that successful results from these studies will lead to
the design of a definitive product registration study.
About Quest PharmaTech Inc.
Quest is a publicly traded, Alberta-based biotechnology company
committed to the development and commercialization of oncology product
candidates. It is developing a series of products for the treatment of
cancer based on its pipeline of SonoLight compounds, and monoclonal
antibodies that target certain tumor antigens that are presented in a
variety of cancers. Quest believes that by combining these antibodies
with other cancer therapies such as chemotherapy or photodynamic
therapy, it can potentially further complement and enhance treatment
outcomes compared to antibody treatment alone.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE Quest PharmaTech Inc.
For further information:
Dr. Madi R. Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email: firstname.lastname@example.org, Internet: www.questpharmatech.com